INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $55,135,972 | +37.3% | 1,041,874 | +20.7% | 0.01% | +18.2% |
| Q3 2022 | $40,152,272 | -12.1% | 862,933 | +7.8% | 0.01% | -8.3% |
| Q2 2022 | $45,677,128 | +17.0% | 800,230 | +25.4% | 0.01% | +33.3% |
| Q1 2022 | $39,035,671 | +27.9% | 637,942 | +9.4% | 0.01% | +50.0% |
| Q4 2021 | $30,525,000 | +129.0% | 583,207 | +63.1% | 0.01% | +100.0% |
| Q3 2021 | $13,331,000 | -23.8% | 357,588 | -16.5% | 0.00% | -25.0% |
| Q2 2021 | $17,491,000 | +83.4% | 428,485 | +52.5% | 0.00% | +100.0% |
| Q1 2021 | $9,536,000 | -43.1% | 281,035 | -46.7% | 0.00% | -50.0% |
| Q4 2020 | $16,768,000 | +86.4% | 527,281 | +50.4% | 0.00% | +100.0% |
| Q3 2020 | $8,997,000 | -43.2% | 350,623 | -43.2% | 0.00% | -60.0% |
| Q2 2020 | $15,844,000 | +72.5% | 617,235 | +3.3% | 0.01% | +66.7% |
| Q1 2020 | $9,183,000 | +19.6% | 597,440 | +166.9% | 0.00% | +50.0% |
| Q4 2019 | $7,679,000 | +262.6% | 223,810 | -21.1% | 0.00% | +100.0% |
| Q3 2019 | $2,118,000 | -50.6% | 283,505 | -14.1% | 0.00% | 0.0% |
| Q2 2019 | $4,284,000 | +6.6% | 330,070 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $4,020,000 | +6.9% | 330,070 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $3,759,000 | -47.5% | 330,070 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $7,163,000 | +22.8% | 330,070 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $5,832,000 | -7.4% | 330,070 | +10.3% | 0.00% | 0.0% |
| Q1 2018 | $6,301,000 | +55.9% | 299,320 | +7.3% | 0.00% | +100.0% |
| Q4 2017 | $4,041,000 | -8.2% | 279,070 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $4,404,000 | +109.7% | 279,070 | +65.1% | 0.00% | +100.0% |
| Q2 2017 | $2,100,000 | -52.7% | 169,070 | -38.1% | 0.00% | -50.0% |
| Q1 2017 | $4,442,000 | +4.8% | 273,354 | -2.7% | 0.00% | 0.0% |
| Q4 2016 | $4,238,000 | +3.7% | 280,850 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $4,088,000 | -46.5% | 280,850 | +42.6% | 0.00% | -50.0% |
| Q2 2016 | $7,648,000 | – | 197,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |